Lymphir Injection, Powder, Lyophilized, For Solution
Product Images NDC 52658-7777

1 FDA label image from Citius Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 1 technical images submitted to the FDA as part of the official labeling for Lymphir (NDC 52658-7777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Citius Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (carton) Lymphir (denileukin Diftitox-cxdl) For Injection 300 Mcg/vial Rx Only (citius Oncology) (Citius Onco Carton Label 1)

Principal Display Panel (carton) Lymphir (denileukin Diftitox-cxdl) For Injection 300 Mcg/vial Rx Only (citius Oncology) (Citius Onco Carton Label 1)
Packaging label for LYMPHIR (denileukin diftitox-cxdl) injection, 300 mcg/vial, a lyophilized powder for intravenous infusion. The label includes dosage instructions, storage guidelines to refrigerate at 2°C to 8°C, and a complete list of vial contents. Manufactured by Citius Oncology, Inc., the label also displays NDC 52658-7777-1 and notes the product is single-dose with no preservatives.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.